米非司酮对子宫肌瘤患者血清IL6和TNFα影响.docVIP

米非司酮对子宫肌瘤患者血清IL6和TNFα影响 　　[摘要] 目的:观察子宫肌瘤患者服用米非司酮治疗后,血清白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)浓度的改变,探讨米非司酮对子宫肌瘤患者的治疗作用。方法:随机选择子宫肌瘤患者86例,每日口服米非司酮10 mg,连用3个月,观察患者治疗前后血清IL-6和TNF-α的变化。结果:子宫肌瘤患者血清IL-6和TNF-α水平总体高于正常人,经米非司酮治疗后,血清IL-6和TNF-α均降低。结论:米非司酮是一种安全、有效的治疗子宫肌瘤的药物。 　　[关键词] 米非司酮;子宫肌瘤;白细胞介素-6;肿瘤坏死因子-α 　　[中图分类号]R711.74 [文献标识码]B [文章编号]1673-7210(2010)04(b)-057-02 　　 　　The influence of Mifepristone on the IL-6 and TNF-α in hysteromyoma 　　XIN Hua1, ZHOU Wei2, DENG Weixiong1, ZHENG Dingrong2 　　(1.Maternity and Child Care Hospital, Baoan District of Shenzhen, Shenzhen 518101, China; 2.Xixiang Peoples Hospital, Baoan District of Shenzhen, Shenzhen 518102, China) 　　[Abstract] Objective: To observe the concentration changes of serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in the patients with hysteromyoma who were treated by Mifepristone, and explore the treatment effect of Mifepristone in the treatment of hysteromyoma. Methods: 86 patients with hysteromyoma were selected randomly, daily oral administration of Mifepristone 10 mg for 3 months, the changes of serum TNF-α and IL-6 before and after treatment were observed. Results: The IL-6 and TNF-α level of hysteromyoma patients were higher than normal, after the treatment with Mifepristone, the serum IL-6 and TNF-α both decreased. Conclusion: Mifepristone is a safe,efficient drug in the treatment of hysteromyoma. 　　[Key words] Hysteromyoma; Mifepristone; IL-6; TNF-α 　　 　　子宫肌瘤是最常见的女性生殖器良性肿瘤,多发于30～50岁的妇女,其发病率为25%～30%。近年研究表明,子宫肌瘤是一种性激素依赖性肿瘤,它的发生发展与孕激素有关,米非司酮为孕激素受体拮抗剂,用药后可使肌瘤体积明显缩小[1];血清白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)是反映机体炎症性反应的重要指标,本研究旨在以子宫肌瘤患者为观察对象,探讨米非司酮治疗前后血清IL-6和TNF-α浓度的改变。 　　1 资料与方法 　　1.1 一般资料 　　2007年1月～2009年10月在我院门诊确诊为子宫肌瘤的患者86例,年龄30～65岁,平均46.4岁。根据临床症状、体征、妇科检查、B超确诊为子宫肌瘤,均有不同程度的临床症状,其中,月经过多、经期延长48例,有压迫症状15例,痛经13例,失血性贫血56例;血红蛋白(Hb)最低 5.6 g/L,平均8.2 g/L。患者均无心、肺、肾疾病等米非司酮禁忌证,用药前均征得患者同意,均除外子宫内膜及宫颈管内恶性病变。所有患者半年内未接受过激素类药物治疗。 　　1.2 用药方法 　　服药时间为月经规律者,从月经周期的第3天开始,每日晚饭后1 h,口服米非司酮(上海华联制药厂生产)10 mg,每天1次,连服3个月,所有入选者在用药之前清晨空腹